LLY
ELI LILLY & Co
$1,065.00
+2.24%
$1.0T
No data for this timeframe.
Vol
Market Cap$1.0T
Cap SizeMega Cap
Analyst ConsensusStrong Buy (77%)
Inst. Holders11 funds
Inst. Value$169.0B
Inst. Activity2 buys / 1 sells
Insider Activity0B / 1S
Insider Net $-$13.6M
Reddit Sentiment56° Neutral
SEC Reports2
Congressional9 trades
Recent Activity
Aug 5, 2026
earnings_calendar
LLY Q2 2026 Earnings After Market Close — 2026-08-05
EPS est: $8.20 | Rev est: $19.7B
May 18, 2026
Insider
Alvarez Ralph sold 12.566 shares
Director @ $988.09 ($12.4K)
May 18, 2026
Insider
LUCIANO JUAN R sold 16.109 shares
Director @ $988.09 ($15.9K)
May 18, 2026
Insider
Sulzberger Gabrielle sold 5.018 shares
Director @ $988.09 ($5.0K)
Apr 22, 2026
Event
Olumiant
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and
Apr 16, 2026
SEC
The U.S. Court of Appeals for the Federal Circuit reversed a lower court's judgment and ruled in favor of Eli Lilly, rei
COURT-RULING — Impact 8/10
Apr 16, 2026
Event
Teva Pharmaceuticals International Gmbh v. Eli Lilly and Company
Court ruling from Court of Appeals for the Federal Circuit. Docket: 24-1094
Apr 2, 2026
Congress
Byron Donalds buy
$1,001 - $15,000 — House
Price Targets
$1,211.03
+13.7% upside
Buy
Current $1,065.00
Low $850.00
Median $1,250.00
High $1,500.00
29 analysts
$850.00
$1,500.00
Analyst Ratings
11Strong Buy
19Buy
8Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 5, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| May 5, 2026 | Guggenheim | REITERATE | Buy → Buy |
| May 4, 2026 | Wolfe Research | REITERATE | Outperform → Outperform |
| May 1, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight → Overweight |
| Apr 22, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $8.81 ▲ +9.0% | $8.16 — $9.36 | 40% YoY | 20 |
| Next Q | $9.40 ▲ +2.2% | $8.79 — $10.69 | 34% YoY | 19 |
| Current FY | $36.19 ▲ +5.6% | $27.66 — $39.91 | 49% YoY | 28 |
| Next FY | $44.44 ▲ +5.5% | $39.45 — $49.75 | 23% YoY | 28 |
Latest Reports
BULLISH
COURT-RULING
8/10
The U.S. Court of Appeals for the Federal Circuit reversed a lower court's judgment and ruled in favor of Eli Lilly, rei
Apr 16, 2026
NEUTRAL
DEFA14A
3/10
Eli Lilly filed a Definitive Additional Materials (DEFA14A) related to a shareholder vote. The filing is routine and doe
Mar 20, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $88.1B | — |
| FMR LLC | $27.6B | — |
| MORGAN STANLEY | $16.8B | — |
| NORGES BANK | $13.0B | NEW |
| BANK OF AMERICA CORP | $11.9B | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 18, 2026 | Alvarez Ralph | A | $12.4K |
| May 18, 2026 | LUCIANO JUAN | A | $15.9K |
| May 18, 2026 | Sulzberger Gabrielle | A | $5.0K |
| May 6, 2026 | LILLY ENDOWMENT | SELL | $13.6M |
| Apr 20, 2026 | Alvarez Ralph | A | $12.4K |
Reddit Sentiment
56°▼
Neutral
Bearish
Neutral
Bullish
Congressional Trades
6 members: 5 buys, 4 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Lizzie Fletcher | D | SELL | $1,001 - $15,000 |
| Byron Donalds | R | BUY | $1,001 - $15,000 |
| Byron Donalds | R | BUY | $1,001 - $15,000 |
11 institutional holders with $169.0B total value (157,295,434 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, MORGAN. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 81,965,974 | $88.1B | 52.1% | — |
| 2 | FMR LLC | 25,721,670 | $27.6B | 16.4% | — |
| 3 | MORGAN STANLEY | 15,593,019 | $16.8B | 9.9% | — |
| 4 | NORGES BANK | 12,074,882 | $13.0B | 7.7% | NEW |
| 5 | BANK OF AMERICA CORP /DE/ | 11,105,586 | $11.9B | 7.1% | — |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 5,758,206 | $6.2B | 3.7% | NEW |
| 7 | WELLS FARGO & COMPANY/MN | 4,851,455 | $5.2B | 3.1% | — |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 165,847 | $178.2M | 0.1% | NEW |
| 9 | DODGE & COX | 42,492 | $45.7M | 0.0% | — |
| 10 | TWO SIGMA INVESTMENTS, LP | 16,068 | $17.3M | 0.0% | NEAR_EXIT -92.1% |
| 11 | Mawer Investment Management Ltd. | 235 | $252.6K | 0.0% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 12,074,882 | — | $13.0B | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 165,847 | — | $178.2M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 202,906 | 16,068 | -92.1% | $17.3M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 73,749 | 202,906 | +175.1% | $154.8M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 261 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | EXIT | 11,324,406 | 0 | -100.0% | $0.00 | 2025-Q3 |
| Duquesne Family Office LLC | EXIT | 100,675 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | NEW | — | 11,324,406 | — | $8.8B | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 15,733 | 73,749 | +368.8% | $57.5M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 96,312 | 261 | -99.7% | $204.7K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 54,120 | 96,312 | +78.0% | $79.5M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 322,690 | 15,733 | -95.1% | $13.0M | 2025-Q1 |
| Mawer Investment Management Ltd. | NEW | — | 300 | — | $247.8K | 2025-Q1 |
| Duquesne Family Office LLC | ADD | 62,190 | 94,830 | +52.5% | $78.3K | 2025-Q1 |
| NORGES BANK | EXIT | 10,891,072 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 3,480,482 | 4,615,775 | +32.6% | $3.6B | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 257,813 | 54,120 | -79.0% | $41.8M | 2024-Q4 |
| Duquesne Family Office LLC | NEW | — | 62,190 | — | $48.0K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 4,835,220 | — | $4.3B | 2024-Q3 |
18 unique insiders with 1 transactions. Net insider value: -$13.6M ($0.00 bought, $13.6M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 18, 2026 | Alvarez Ralph | Director | A | 12.566 | $988.09 | $12.4K |
| May 18, 2026 | LUCIANO JUAN R | Director | A | 16.109 | $988.09 | $15.9K |
| May 18, 2026 | Sulzberger Gabrielle | Director | A | 5.018 | $988.09 | $5.0K |
| May 6, 2026 | LILLY ENDOWMENT INC | SELL | 13,620 | $995.23 | $13.6M | |
| Apr 20, 2026 | Alvarez Ralph | Director | A | 13.498 | $919.90 | $12.4K |
| Apr 20, 2026 | Fyrwald J Erik | Director | A | 10.78 | $919.90 | $9.9K |
| Apr 20, 2026 | LUCIANO JUAN R | Director | A | 17.303 | $919.90 | $15.9K |
| Apr 20, 2026 | Sulzberger Gabrielle | Director | A | 5.39 | $919.90 | $5.0K |
| Mar 16, 2026 | Fyrwald J Erik | Director | A | 10.026 | $989.12 | $9.9K |
| Mar 16, 2026 | LUCIANO JUAN R | Director | A | 16.092 | $989.12 | $15.9K |
| Mar 16, 2026 | Sulzberger Gabrielle | Director | A | 5.013 | $989.12 | $5.0K |
| Mar 16, 2026 | Alvarez Ralph | Director | A | 12.553 | $989.12 | $12.4K |
| Feb 9, 2026 | Rau Diogo | EVP & CIDO | A | 4,599.164 | $1,044.67 | $4.8M |
| Feb 9, 2026 | Custer Kenneth L. | EVP & President, Card Met Hlth | A | 659.28 | $1,044.67 | $688.7K |
| Feb 9, 2026 | Montarce Lucas | EVP & CFO | A | 1,365.47 | $1,044.67 | $1.4M |
| Feb 9, 2026 | Yuffa Ilya | EVP&Pres, LLY USA&Global Capab | A | 4,162.504 | $1,044.67 | $4.3M |
| Feb 9, 2026 | Zakrowski Donald A | SVP, Finance, & CAO | A | 583.784 | $1,044.67 | $609.9K |
| Feb 9, 2026 | Zakrowski Donald A | SVP, Finance, & CAO | A | 199.472 | $0.00 | $0.00 |
| Feb 9, 2026 | Ricks David A | President, Chair, and CEO | A | 38,913.584 | $1,044.67 | $40.7M |
| Feb 9, 2026 | Brown Adrienne S | EVP, President LLY Imm | A | 1,196.308 | $1,044.67 | $1.2M |
| Feb 9, 2026 | Dozier Eric | EVP, Chief People Officer | A | 3,512.294 | $1,044.67 | $3.7M |
| Feb 9, 2026 | Hakim Anat | EVP, GC & Secretary | A | 8,277.919 | $1,044.67 | $8.6M |
| Feb 9, 2026 | Skovronsky Daniel | EVP, CS&PO & Pres. LRL | A | 15,547.862 | $1,044.67 | $16.2M |
| Feb 9, 2026 | Hernandez Edgardo | EVP & Pres., Mfg. Operations | A | 4,383.734 | $1,044.67 | $4.6M |
| Feb 9, 2026 | Van Naarden Jacob | EVP,Pres LLY Oncology&HdCorpBD | A | 4,865.888 | $1,044.67 | $5.1M |
| Feb 9, 2026 | Rau Diogo | EVP & CIDO | A | 4,432.32 | $1,044.67 | $4.6M |
| Feb 9, 2026 | Jonsson Patrik | EVP & President, LLY Int'l | A | 4,818.052 | $1,044.67 | $5.0M |
| Feb 1, 2026 | Hernandez Edgardo | EVP & Pres., Mfg. Operations | M | 3,572 | $0.00 | $0.00 |
| Feb 1, 2026 | Dozier Eric | EVP, Chief People Officer | M | 2,858 | $0.00 | $0.00 |
| Feb 1, 2026 | Van Naarden Jacob | EVP,Pres LLY Oncology&HdCorpBD | M | 4,108 | $0.00 | $0.00 |
| Feb 1, 2026 | Van Naarden Jacob | EVP,Pres LLY Oncology&HdCorpBD | F | 1,909.375 | $1,037.15 | $2.0M |
| Feb 1, 2026 | Van Naarden Jacob | EVP,Pres LLY Oncology&HdCorpBD | M | 4,108 | $0.00 | $0.00 |
| Feb 1, 2026 | Ricks David A | President, Chair, and CEO | M | 31,932 | $0.00 | $0.00 |
| Feb 1, 2026 | Ricks David A | President, Chair, and CEO | M | 31,932 | $0.00 | $0.00 |
| Feb 1, 2026 | Ricks David A | President, Chair, and CEO | F | 14,296.654 | $1,037.15 | $14.8M |
| Feb 1, 2026 | Rau Diogo | EVP & CIDO | M | 3,752 | $0.00 | $0.00 |
| Feb 1, 2026 | Rau Diogo | EVP & CIDO | F | 1,673.538 | $1,037.15 | $1.7M |
| Feb 1, 2026 | Rau Diogo | EVP & CIDO | M | 3,752 | $0.00 | $0.00 |
| Feb 1, 2026 | Hernandez Edgardo | EVP & Pres., Mfg. Operations | F | 1,591.452 | $1,037.15 | $1.7M |
| Feb 1, 2026 | Hernandez Edgardo | EVP & Pres., Mfg. Operations | M | 3,572 | $0.00 | $0.00 |
| Feb 1, 2026 | Skovronsky Daniel | EVP, CS&PO & Pres. LRL | M | 12,684 | $0.00 | $0.00 |
| Feb 1, 2026 | Skovronsky Daniel | EVP, CS&PO & Pres. LRL | F | 5,641.249 | $1,037.15 | $5.9M |
| Feb 1, 2026 | Skovronsky Daniel | EVP, CS&PO & Pres. LRL | M | 12,684 | $0.00 | $0.00 |
| Feb 1, 2026 | Dozier Eric | EVP, Chief People Officer | M | 2,858 | $0.00 | $0.00 |
| Feb 1, 2026 | Dozier Eric | EVP, Chief People Officer | F | 1,272.992 | $1,037.15 | $1.3M |
| Feb 1, 2026 | Hakim Anat | EVP, GC & Secretary | M | 6,700 | $0.00 | $0.00 |
| Feb 1, 2026 | Hakim Anat | EVP, GC & Secretary | F | 2,953.395 | $1,037.15 | $3.1M |
| Feb 1, 2026 | Hakim Anat | EVP, GC & Secretary | M | 6,700 | $0.00 | $0.00 |
| Feb 1, 2026 | Jonsson Patrik | EVP & President, LLY Int'l | M | 3,930 | $0.00 | $0.00 |
| Feb 1, 2026 | Jonsson Patrik | EVP & President, LLY Int'l | F | 1,752.071 | $1,037.15 | $1.8M |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.5/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (77% buy). Based on 39 analysts: 11 strong buy, 19 buy, 8 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$1,211.03 mean target
+13.7% upside
Buy (1.71)
$850.00 Low
$1,500.00 High
| Metric | Value |
|---|---|
| Current Price | $1,065.00 |
| Target Low | $850.00 |
| Target Mean | $1,211.03 |
| Target Median | $1,250.00 |
| Target High | $1,500.00 |
| # Analysts | 29 |
| Recommendation | Buy (1.71) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$8.81 | $8.16 | $9.36 | 39.5% | +9.0% | 17↑ 1↓ | $20.5B | 31.6% | 20 |
| Next Q 2026-09-30 |
$9.40 | $8.79 | $10.69 | 33.9% | +2.2% | 13↑ 4↓ | $21.6B | 22.6% | 19 |
| Current FY 2026-12-31 |
$36.19 | $27.66 | $39.91 | 49.5% | +5.6% | 24↑ 2↓ | $85.4B | 31.0% | 28 |
| Next FY 2027-12-31 |
$44.44 | $39.45 | $49.75 | 22.8% | +5.5% | 21↑ 2↓ | $98.0B | 14.8% | 28 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $8.805 | |
| 7d ago | $8.808 | -0.003 |
| 30d ago | $8.079 | +0.726 |
| 60d ago | $8.123 | +0.683 |
| 90d ago | $8.075 | +0.730 |
13 analyst firms have rated this stock: 1 upgrades, 1 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 5, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| May 5, 2026 | Guggenheim | REITERATE | Buy | Buy |
| May 4, 2026 | Wolfe Research | REITERATE | Outperform | Outperform |
| May 1, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Apr 22, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Apr 2, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Mar 30, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | HSBC | DOWNGRADE | Hold | Reduce |
| Feb 25, 2026 | RBC Capital | INITIATE | — | Outperform |
| Feb 20, 2026 | Barclays | INITIATE | — | Overweight |
| Feb 10, 2026 | Freedom Broker | UPGRADE | Hold | Buy |
| Feb 9, 2026 | Deutsche Bank | MAINTAIN | Buy | Buy |
| Feb 5, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Feb 5, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Feb 5, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 5, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Feb 2, 2026 | Freedom Broker | MAINTAIN | Hold | Hold |
| Jan 20, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Dec 15, 2025 | B of A Securities | MAINTAIN | Buy | Buy |
| Dec 10, 2025 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Dec 4, 2025 | BMO Capital | MAINTAIN | Outperform | Outperform |
| Dec 3, 2025 | Guggenheim | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 11 | 19 | 8 | 1 | 0 | 77% | |
| Apr 1, 2026 | 12 | 18 | 8 | 1 | 0 | 77% | |
| Mar 1, 2026 | 12 | 18 | 9 | 0 | 0 | 77% | |
| Feb 1, 2026 | 11 | 16 | 10 | 0 | 0 | 73% | |
| Jan 1, 2026 | 11 | 17 | 9 | 0 | 0 | 76% | |
| Dec 1, 2025 | 10 | 18 | 9 | 0 | 0 | 76% | |
| Nov 1, 2025 | 9 | 18 | 9 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
6 members of Congress traded this stock: 5 buys, 4 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Apr 8, 2026 | Lizzie Fletcher | D | HOUSE | SELL | $1,001 - $15,000 | Eli Lilly and Co | May 1, 2026 (24d) |
| Apr 2, 2026 | Byron Donalds | R | HOUSE | BUY | $1,001 - $15,000 | Eli Lilly and Co | May 14, 2026 (43d) |
| Apr 2, 2026 | Byron Donalds | R | HOUSE | BUY | $1,001 - $15,000 | Eli Lilly and Co | May 14, 2026 (43d) |
| Mar 13, 2026 | Gilbert Cisneros | D | HOUSE | SELL | $1,001 - $15,000 | Eli Lilly and Co | Apr 8, 2026 (27d) |
| Feb 26, 2026 | David Taylor | R | HOUSE | BUY | $1,001 - $15,000 | Eli Lilly and Co | Mar 9, 2026 (12d) |
| Feb 13, 2026 | Angus King | O | SENATE | SELL | $1,001 - $15,000 | Eli Lilly and Co | Mar 24, 2026 (39d) |
| Feb 9, 2026 | David Taylor | R | HOUSE | SELL | $1,001 - $15,000 | Eli Lilly and Co | Feb 23, 2026 (15d) |
| Dec 29, 2025 | Angus King | O | SENATE | BUY | $1,001 - $15,000 | Eli Lilly and Co | Jan 26, 2026 (29d) |
| Dec 29, 2025 | Markwayne Mullin | R | SENATE | BUY | $15,001 - $50,000 | Eli Lilly and Co | Jan 16, 2026 (19d) |
56°
Neutral
Bearish
Neutral
Bullish
30 mentions
13 bullish
9 bearish
27 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 21, 2026 | 2 | 33° Cool | 0 | 2 | 2 |
| May 21, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 15, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| May 15, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| May 11, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 11, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 11, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 1, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 30, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 26, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| Apr 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 24, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| Apr 24, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 11, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 11, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 9, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 9, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 29, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 29, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 19, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 19, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Feb 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Does anyone here sell OTM naked calls of expensive stock taking the chance of being assigned?
▲ 13
💬 64
⚡ 0.8
Should I see my 3 individual stocks and buy the SP 500?
▲ 1
💬 1
⚡ 0.5
Eli Lilly $LLY stock up 2.24% on 21 May - retatrutide Phase 3 TRIUMPH-1 data shows 28.3% average weight loss
▲ 1
💬 0
⚡ 0.5
Finding investments using Value Score
▲ 1
💬 0
⚡ 0.5
More optimism across the market today
▲ 1
💬 0
⚡ 0.5
Eli Lilly $LLY stock up 2.24% - retatrutide Phase 3 TRIUMPH-1 data shows 28.3% average weight loss
▲ 1
💬 0
⚡ 0.5
LLY just dropped a $149/month weight loss pill shipping today - analysts project $101B peak revenue
▲ 1
💬 1
⚡ 0.5
UNH or LLY - Which do you prefer?
▲ 1
💬 1
⚡ 0.5
$LLY All in
▲ 1
💬 0
⚡ 0.5
Thoughts in $MCD
▲ 1
💬 0
⚡ 0.5
Why is LLY Shitting The Bed?
▲ 1
💬 0
⚡ 0.5
Aug 5, 2026
earnings_calendar
LLY Q2 2026 Earnings After Market Close — 2026-08-05
EPS est: $8.20 | Rev est: $19.7B
May 23, 2026
Clinical Trial
Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
Phase Phase 2 — TERMINATED
May 23, 2026
Clinical Trial
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Phase Phase 3 — COMPLETED
May 23, 2026
Clinical Trial
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
Phase Phase 2 — COMPLETED
May 18, 2026
Clinical Trial
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Phase Phase 3 — ACTIVE_NOT_RECRUITING
May 18, 2026
clinical_trial_readout
T-90d Trial Readout: Retatrutide (Phase 3)
Trial: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With
May 18, 2026
Clinical Trial
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Phase Phase 2 — ACTIVE_NOT_RECRUITING
May 18, 2026
clinical_trial_readout
T-90d Trial Readout: Mazdutide (Phase 2)
Trial: A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Sponsor: Eli Lilly and Company
Phase: Phase 2 | S
May 17, 2026
clinical_trial_readout
Results Pending: Orforglipron (Phase 3) — Completed 62d ago
Trial: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at
May 14, 2026
clinical_trial_readout
Results Pending: Lebrikizumab (Phase 3) — Completed 21d ago
Trial: Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
Sponsor: Almirall,
May 12, 2026
clinical_trial_readout
T-90d Trial Readout: Mazdutide (Phase 2)
Trial: A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Sponsor: Eli Lilly and Company
Phase: Phase 2 | S
May 11, 2026
clinical_trial_readout
T-90d Trial Readout: Retatrutide (Phase 3)
Trial: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: Retatrutide (Phase 3)
Trial: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: Mazdutide (Phase 2)
Trial: A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Sponsor: Eli Lilly and Company
Phase: Phase 2 | S
May 3, 2026
clinical_trial_readout
T-90d Trial Readout: Mazdutide (Phase 2)
Trial: A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Sponsor: Eli Lilly and Company
Phase: Phase 2 | S
May 3, 2026
clinical_trial_readout
T-90d Trial Readout: Retatrutide (Phase 3)
Trial: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With
Apr 30, 2026
earnings_calendar
LLY Q1 2026 Earnings After Market Close — 2026-04-30
EPS est: $7.33 | Rev est: $17.6B
Apr 30, 2026
earnings_calendar
LLY Q1 2026 Earnings Scheduled — 2026-04-30
Apr 27, 2026
dark_pool
Dark Pool: LLY — 5.0M shares, 170,192 trades
Week starting 2026-04-27. Total ATS volume: 5,015,892 shares across 170,192 trades.
Apr 23, 2026
short_volume
Short Volume: LLY — 58.3% short (0.5M / 0.8M)
Short: 451,045 | Exempt: 19 | TRF Vol: 774,222 | Short Ratio: 58.3% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
FDA
Olumiant
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS WARNING: SERIOUS INFECTIONS, MORTALITY,
Apr 16, 2026
Enforcement
Teva Pharmaceuticals International Gmbh v. Eli Lilly and Company
Court ruling from Court of Appeals for the Federal Circuit. Docket: 24-1094
Apr 6, 2026
Enforcement
HSR Early Termination: Eli Lilly and Company; CSL Limited
The FTC granted early termination of the HSR Act waiting period for a transaction involving Eli Lilly and Company; CSL Limited.
Apr 1, 2026
FDA
FOUNDAYO
Original Approval — Type 1 - New Molecular Entity — ORFORGLIPRON — ORAL
Apr 1, 2026
FDA
FOUNDAYO
WARNING: RISK OF THYROID C-CELL TUMORS In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in